Device Maker Medmari Expects High Sales Through Reclassification Of Its Rapid HIV Test In China
This article was originally published in PharmAsia News
SHANGHAI - China's State FDA has approved and reclassified Canadian device maker MedMari's rapid HIV test as a medical device in China, which will increase sales opportunities for the product, the company announced
You may also be interested in...
SHANGHAI - China issued its long-awaited three-year plan for its healthcare reform, and unveiled how the country will allocate RMB 850 billion ($124 billion) in the next three years
SHANGHAI- China's medical device market has reached RMB 83 billion ($12.1 billion), roughly one-eighth of the total healthcare industry, according to a report by Frost & Sullivan
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).